https://www.selleckchem.com/CDK.html
Introduction China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020. However, there is still a lack of evaluation evidence on the value of PER in China. Methods This study selected a health system perspective. A Markov model was established to simulate the lifelong transition of different response levels and calculate the
Like
Comment
Share
